Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma (Phase 2)
Adrenocortical Carcinoma (Phase 2)
Astrocytoma (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Merkel Cell (Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Colonic Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Intestinal Neoplasms (Phase 2)
Kidney Neoplasms (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Multiple Myeloma (Phase 2)
Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors, Primitive (Phase 2)
Oligodendroglioma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pituitary Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Sarcoma (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Stomach Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Vulvar Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue